Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Neuro Oncol ; 26(2): 266-278, 2024 02 02.
Artículo en Inglés | MEDLINE | ID: mdl-37715782

RESUMEN

BACKGROUND: Neuroligin 4 X-linked (NLGN4X) harbors a human leukocyte antigen (HLA)-A*02-restricted tumor-associated antigen, overexpressed in human gliomas, that was found to induce specific cytotoxic T cell responses following multi-peptide vaccination in patients with newly diagnosed glioblastoma. METHODS: T cell receptor (TCR) discovery was performed using droplet-based single-cell TCR sequencing of NLGN4X-tetramer-sorted T cells postvaccination. The identified TCR was delivered to Jurkat T cells and primary human T cells (NLGN4X-TCR-T). Functional profiling of NLGN4X-TCR-T was performed by flow cytometry and cytotoxicity assays. Therapeutic efficacy of intracerebroventricular NLGN4X-TCR-T was assessed in NOD scid gamma (NSG) major histocompatibility complex (MHC) I/II knockout (KO) (NSG MHC I/II KO) mice bearing NLGN4X-expressing experimental gliomas. RESULTS: An HLA-A*02-restricted vaccine-induced T cell receptor specifically binding NLGN4X131-139 was applied for preclinical therapeutic use. Reactivity, cytotoxicity, and polyfunctionality of this NLGN4X-specific TCR are demonstrated in various cellular models. Intracerebroventricular administration of NLGN4X-TCR-T prolongs survival and leads to an objective response rate of 44.4% in experimental glioma-bearing NSG MHC I/II KO mice compared to 0.0% in control groups. CONCLUSION: NLGN4X-TCR-T demonstrate efficacy in a preclinical glioblastoma model. On a global scale, we provide the first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.Keywords cell therapy | glioblastoma | T cell receptor | tumor antigen.


Asunto(s)
Vacunas contra el Cáncer , Glioblastoma , Ratones , Animales , Humanos , Glioblastoma/genética , Glioblastoma/terapia , Vacunas contra el Cáncer/uso terapéutico , Vacunas de Subunidad , Receptores de Antígenos de Linfocitos T , Linfocitos T , Antígenos de Neoplasias/genética , Moléculas de Adhesión Celular Neuronal
3.
Exp Dermatol ; 26(5): 423-430, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-27892606

RESUMEN

SVEP1 is a recently identified multidomain cell adhesion protein, homologous to the mouse polydom protein, which has been shown to mediate cell-cell adhesion in an integrin-dependent manner in osteogenic cells. In this study, we characterized SVEP1 function in the epidermis. SVEP1 was found by qRT-PCR to be ubiquitously expressed in human tissues, including the skin. Confocal microscopy revealed that SVEP1 is normally mostly expressed in the cytoplasm of basal and suprabasal epidermal cells. Downregulation of SVEP1 expression in primary keratinocytes resulted in decreased expression of major epidermal differentiation markers. Similarly, SVEP1 downregulation was associated with disturbed differentiation and marked epidermal acanthosis in three-dimensional skin equivalents. In contrast, the dispase assay failed to demonstrate significant differences in adhesion between keratinocytes expressing normal vs low levels of SVEP1. Homozygous Svep1 knockout mice were embryonic lethal. Thus, to assess the importance of SVEP1 for normal skin homoeostasis in vivo, we downregulated SVEP1 in zebrafish embryos with a Svep1-specific splice morpholino. Scanning electron microscopy revealed a rugged epidermis with perturbed microridge formation in the centre of the keratinocytes of morphant larvae. Transmission electron microscopy analysis demonstrated abnormal epidermal cell-cell adhesion with disadhesion between cells in Svep1-deficient morphant larvae compared to controls. In summary, our results indicate that SVEP1 plays a critical role during epidermal differentiation.


Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Epidermis/metabolismo , Epidermis/ultraestructura , Queratinocitos/metabolismo , Animales , Adhesión Celular , Diferenciación Celular , Expresión Génica , Humanos , Ratones Noqueados , Cultivo Primario de Células , Pez Cebra
4.
J Immunol ; 172(10): 6398-406, 2004 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-15128831

RESUMEN

In certain models of allergic airway disease, mast cells facilitate the development of inflammation and airway hyper-responsiveness (AHR). To define the role of the high affinity IgE receptor (FcepsilonRI) in the development of AHR, mice with a disruption of the alpha subunit of the high affinity IgE receptor (FcepsilonRI(-/-)) were exposed on 10 consecutive days to nebulized OVA. Forty-eight hours after the last nebulization, airway responsiveness was monitored by the contractile response of tracheal smooth muscle to electrical field stimulation (EFS). After the 10-day OVA challenge protocol, wild-type mice demonstrated increased responsiveness to EFS, whereas similarly challenged FcepsilonRI(-/-) mice showed a low response to EFS, similar to nonexposed animals. Further, allergen-challenged FcepsilonRI(-/-) mice showed less airway inflammation, goblet cell hyperplasia, and lower levels of IL-13 in lung homogenates compared with the controls. IL-13-deficient mice failed to develop an increased response to EFS or goblet cell hyperplasia after the 10-day OVA challenge. We transferred bone marrow-derived mast cells from wild-type mice to FcepsilonRI(-/-) mice 1 day before initiating the challenge protocol. After the 10-day OVA challenge, recipient FcepsilonRI(-/-) mice demonstrated EFS-induced responses similar to those of challenged wild-type mice. Transferred mast cells could be detected in tracheal preparations. These results show that FcepsilonRI is important for the development of AHR after an aerosolized allergen sensitization protocol and that this effect is mediated through FcepsilonRI on mast cells and production of IL-13 in the lung.


Asunto(s)
Adyuvantes Inmunológicos , Alérgenos/administración & dosificación , Hiperreactividad Bronquial/inmunología , Interleucina-13/fisiología , Mastocitos/inmunología , Receptores de IgE/fisiología , Traslado Adoptivo , Aerosoles , Alérgenos/inmunología , Animales , Trasplante de Médula Ósea/inmunología , Hiperreactividad Bronquial/genética , Estimulación Eléctrica , Femenino , Células Caliciformes/inmunología , Células Caliciformes/patología , Hiperplasia , Inmunoglobulina E/biosíntesis , Inmunoglobulina G/biosíntesis , Inflamación/genética , Inflamación/patología , Interleucina-13/deficiencia , Interleucina-13/genética , Interleucina-13/metabolismo , Leucopenia/genética , Leucopenia/inmunología , Pulmón/inmunología , Pulmón/patología , Mastocitos/patología , Mastocitos/trasplante , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Mutantes , Ratones Transgénicos , Nebulizadores y Vaporizadores , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Receptores de IgE/deficiencia , Receptores de IgE/genética , Tráquea/citología , Tráquea/inmunología , Tráquea/metabolismo
5.
Am J Respir Crit Care Med ; 169(6): 726-32, 2004 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-14701711

RESUMEN

Ozone (O3) can induce airway hyperresponsiveness (AHR) and neutrophilic inflammation. We evaluated the role of complement in development of AHR and inflammation after acute O3 exposure in mice. Mice were exposed to O3 at 2 ppm for 3 hours, and airway responsiveness to methacholine was measured 8 hours after O3 exposure. Complement was depleted or inhibited by intraperitoneal injection of cobra venom factor (CVF) or complement receptor-related gene y (Crry)-Ig, a potent C3 convertase inhibitor; neutrophils were depleted using an antineutrophil monoclonal antibody. CVF attenuated the development of AHR by O3. Administration of Crry-Ig also prevented the development of AHR. Bronchoalveolar lavage (BAL) fluid neutrophilia after O3 exposure was significantly decreased by administration of either CVF or Crry-Ig. Increased BAL fluid total protein after O3 exposure was lowered by depletion or inhibition of complement. In contrast to the effects of complement inhibition or depletion, depletion of BAL neutrophil counts by more than 90% with the monoclonal antibody did not affect the development of AHR after O3 exposure. These data indicated that activation of the complement system follows acute O3 exposure and is important to the development of AHR and airway neutrophilia. However, this neutrophil response does not appear necessary for the development of AHR.


Asunto(s)
Hiperreactividad Bronquial/fisiopatología , Activación de Complemento/fisiología , Proteínas Inactivadoras de Complemento/farmacología , Venenos Elapídicos/farmacología , Inmunoglobulinas/fisiología , Receptores de Complemento/fisiología , Animales , Hiperreactividad Bronquial/inducido químicamente , Activación de Complemento/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Ratones , Ratones Endogámicos C57BL , Activación Neutrófila/fisiología , Oxidantes Fotoquímicos/toxicidad , Ozono/toxicidad , Receptores de Complemento 3b
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...